Tissue CA-19.9 content in colorectal adenomas and its value in the assessment of dysplasia;Detección de CA-19.9 citosólico en adenomas colorrectales. Utilidad en el diagnóstico de la displasia

Revista Espanola de Enfermedades Digestivas

Volumn 96, Issue 4, 2004, Pages 246-254

  Salces, Immaculada ^a   Vegh, I ^a   Rodriguez Munoz S ^a   Colina, F ^a   Perez A ^a   Soto, S ^a   Sanchez F ^a   de la Cruz, J ^a   Solis Herruzo J A ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

CA 19.9; Colonic polyps; Colorectal adenoma; Dysplasia grade; Tissue tumor markers

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ADENOMATOUS POLYP; ARTICLE; CANCER RISK; COLON MUCOSA; COLORECTAL ADENOMA; COLORECTAL CARCINOMA; COLORECTAL DISEASE; COLORECTAL DYSPLASIA; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSOL; DIAGNOSTIC VALUE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MEASUREMENT; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RECTUM MUCOSA; RISK ASSESSMENT; TUMOR CLASSIFICATION; TUMOR VOLUME;

ADENOCARCINOMA; ADENOMA; CA-19-9 ANTIGEN; COLONIC POLYPS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; SEVERITY OF ILLNESS INDEX;

EID: 2942513455     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Winawer SJ. Natural history of colorectal cancer. Am J Med 1999; 106:3S-6S; discussion 50S-51S.
2. Winawer S, Zauber A. The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 2002; 12: 1-9,v.
3. Winamer S, Fletcher R, Douglas R, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and survillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 2003;124: 544-60.
4. Itzkowitz SH, Kim YS. Colonic polyps and polyposis syndromes. En: Feldman M. Scharschmidt BF, Sleisenger MH, eds. Sleisenger and Fordtran's Gastrointestinal and Liver disease. Pathophisiology, Diagnosis, Management. 6th Ed; Vol. II. Philadelphia: WB. Saunders. 1998. p. 1865-905.
5. Itzkowitz SH. Gastrointestinal adenomatous polyps. Semin Gastrointest Dis 1996; 7: 105-16.
6. Winawer SJ. Appropriate intervals for surveillance. Gastrointest Endosc 1999; 49: S63-66.
7. Brown IJ, Smeeton NC, Dixon MF. Assessment of dysplasia in colorectal adenomas: an observer variation and morphonietric study. J Clin Pathol 1985; 38: 174-9.
8. Dixon MF, Brown LJ, Gilmour HM, Price AB, Smeeton NC, Talbot IC, et al. Observer variation in assessment of dysplasia in ulcerative colitis. Histopathology 1988; 13: 385-97.
9. Jensen P, Krogsgaard M, Christiansen J, Braendstrup 0, Johansen A, Olsen J. Observer variability in the assessment of type and dysplasia of colorectal adenomas, analyzed using kappa statistics. Dis Colon Rectum 1995; 38: 195-8.
10. Rex D, Alikhan M, Cummings O, Ulbright TM. Accuracy of pathologic interpretation of colorectal polyps by general pathologists in community practice. Gastrointest Endosc 1999; 50: 468-74.
11. Bond JH. Follow-up after polypectomy: Consensus? Eur J Cancer 1995; 31A: 1141-4.
12. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5: 957-71.
13. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981; 212: 53-5.
14. Magnani JL, Brockhaus M, Smith DF, Ginsburg V, Blaszczyk Mitcholl KF, et al. A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science 1981; 212: 55-6.
15. Koprowski H, Brockhaus M, Blaszczyk M, Magnani J, Steplewski Z, Ginsburg V. Lewis Blood-type may affect the incidence of gastrointestinal cancer. Lancet 1982; 1: 1332-3.
16. Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, et al. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982; 257: 14365-9.
17. Lindholm L, Holmgren J, Svennerholm L, Fredman P, Nilsson O, Persson B, et al. Monoclonal, antibodies against gastrointestinal tumour-associated antigens isolated as monosialogangliosides. Int Arch Allergy Appl Immunol 1983; 71: 178-81.
18. Fukuta S, Magnani JL, Gaur PK, Ginsburg V. Monoclonal antibody CC3C195, which detects,cancer-associated antigens in serum, binds to the human Lea blood group antigen and to its sialylated derivative. Arch Biochem Biophys 1987; 255: 214-6.
19. Filella X, Molina R, Grau JJ, Piqué JM, García-Valdecasas JC, Astudillo E. et al. Prognostic value of CA 19.9 levels in colorectal cancer. Ann Surg 1992; 216: 55-9.
20. Fischbach W, Mössner J. Tissue concentrations of CEA and CA 19.9 in the carcinogenesis of colorectal carcinoma exemplified by the adenoma-carcinoma sequence. Res Exp Mod 1988; 188: 101-14.
21. Imamura Y, Yasutake K, Yoshimura Y, et al. Contents of tissue CEA and CA 19.9 in colonic polyp and colorectal cancer, and their clinical significance. Gastroenterol Jpn 1990; 25: 186-92.
22. Konishi F, Morson BC. Pathology of colorectal adenomas: a colonoscopic survey. J Clin Pathol 1982; 35: 830-41.
23. Maratka Z. Terminology, definitions and diagnostic criteria in digestive endoscopy. With the collaboration of the members of the Terminology Committee of the World. Society of Digestive Endoscopy/OMED. Scand J Gastroenterol 1984; 103 (Supl.): 1-74.
24. Blackstone MO. Colonic polyps. En: Endoscopic interpretation. Normal and pathologic appearances of the gastrointestinal tract. New York: Raven Press, 1994: 429-49.
25. Lowry OH, Rosebrough NJ, Farr AL Protein measurement with the Folin-phenol reagent. J Biol Chem 1951; 193: 265-75.
26. O'Brien MJ, Winner SJ, Zauber AG, Gottlieb LS, Sternberg SS, Diaz B, et al. The National Polyp Study. Patient and polyp characteristics associated with high-grade dysplasia in colorectal adenomas. Gastroenterology 1990; 98: 371-9.
27. Linares-Santiago F, Gómez-Parra M, Pellicer-Bautista F, Romero-Castro R, Caunedo-Álvarez A, Mendoza-Olivares FJ, et al. The assessment of colonic polyps found via colonoscopy. Gastroenterol Hepatol 1999; 22: 273-8.
28. Compton C, Henson D, Hutter R, Sobin LH, Bowman HE. Updated protocol for the examination of specimens removed from patients with colorectal carcinoma. A basis for checklists. Arch Pathol Lab Med 1997; 12: 1247-54.
29. Altman DG, Bland JM. Diagnostic tests 1: sensitivity and specificity. BMJ 1994; 308:1552.
30. Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ 1994;309:102.
31. Altman DG, Bland JM. Diagnostic tests 3: receiver operating characteristic plots. BMJ 1994; 309: 188.
32. Zweig MH, Campbell G. Receiver operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993,39: 561-77.
33. Altman DG. ROC curves and confidence intervals: getting them right. Heart 2000; 83: 236.
34. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36.
35. Wagener Ch, Müller-Wallraf R, Nisson S, Groner J, Breuer H. Localization and concentration of carcinoembryonic antigen (CEA) in gastrointestinal tumors: correlation with CEA levels in plasma. J Natl Cancer Inst 198 1; 67: 539-47.